Τίτλος:
In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Persistent immune activation and inflammation are lying behind HIV-infection even in the setting of ART mediated viral suppression. The purpose of this study is to define the in vivo effect of two first-line ART regimens on certain inflammatory mediators in male HIV patients. Methods. Male, naive, HIV-infected volunteers were assigned either to tenofovir-DF/emtricitabine/ efavirenz (Group-T) or abacavir/lamivudine/efavirenz (Group-A). Platelet Activating Factor (PAF) levels and metabolic enzymes together with HIV-implicated cytokines (IL-1beta, IL-6, IL-8, IL-10, IL-12p70, TNFa) and VEGF were determined for a 12-month period. Differences within each group were determined by non-parametric Friedman and Wilcoxon test, while the differences between the groups were checked by ANOVA repeated measures. Results: Both ART regimens present pronounced effect on inflammatory mediators, resulting in decreased PAF levels and Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity for tenofovir-containing regimen and same as baseline PAF levels with a peak though at the 3rd month as well as elevated Lp-PLA2 activity for abacavir-containing regimen. Conclusions: Studies regarding the effect of first-line ART regimens on inflammation may be beneficial in preventing chronic morbidities during HIV-treatment. From this point of view, the present study suggests an anti-inflammatory effect of tenofovir-containing ART, while the temporary increase of PAF levels in abacavir-containing ART may be the link between the reported cardiovascular risk and abacavir administration. © 2014 Papakonstantinou et al.; licensee BioMed Central Ltd.
Συγγραφείς:
Papakonstantinou, V.D.
Chini, M.
Mangafas, N.
Stamatakis, G.M.
Tsogas, N.
Tsoupras, A.B.
Psarra, K.
Fragopoulou, E.
Antonopoulou, S.
Gargalianos, P.
Demopoulos, C.A.
Lazanas, M.-C.
Περιοδικό:
Lipids in Health and Disease
Εκδότης:
BioMed Central Ltd.
Λέξεις-κλειδιά:
1 alkyl 2 acetylglycerophosphocholine esterase; abacavir; antiretrovirus agent; efavirenz; emtricitabine; high density lipoprotein; interleukin 10; interleukin 12p70; interleukin 1beta; interleukin 6; interleukin 8; lamivudine; low density lipoprotein; tenofovir; thrombocyte activating factor; tumor necrosis factor alpha; vasculotropin; adenine; anti human immunodeficiency virus agent; benzoxazine derivative; efavirenz; interleukin 10; interleukin 6; interleukin 8; lamivudine; phosphonic acid derivative; tenofovir; thrombocyte activating factor; tumor necrosis factor alpha, adult; article; cardiovascular risk; cholesterol blood level; clinical article; enzyme activity; enzyme linked immunosorbent assay; human; Human immunodeficiency virus infection; in vivo study; leukocyte; male; thrombocyte; analogs and derivatives; animal; HIV Infections; metabolism; middle aged, Human immunodeficiency virus, Adenine; Adult; Animals; Anti-HIV Agents; Benzoxazines; HIV Infections; Humans; Interleukin-10; Interleukin-6; Interleukin-8; Lamivudine; Male; Middle Aged; Organophosphonates; Platelet Activating Factor; Tumor Necrosis Factor-alpha
DOI:
10.1186/1476-511X-13-90
